Last updated: February 14, 2026
Overview of the Drug
The NDC 51407-0068 corresponds to Sofosbuvir/Ledipasvir (Harvoni), a fixed-dose combination antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It marked a significant advancement in HCV therapy due to high cure rates, simplified dosing, and reduced treatment duration.
Market Size & Demand
Global Hepatitis C Market
- The hepatitis C antiviral market was valued at approximately $20 billion in 2022.
- Expected Compound Annual Growth Rate (CAGR): 8% from 2023 to 2028.
- Major markets: North America, Europe, Asia-Pacific, Latin America, Middle East, Africa.
Patient Population
- Approximately 58 million people globally infected with HCV.
- The U.S. market: about 2.4 million diagnosed cases.
- Treatment-eligible population: estimated at 1 million annually in the U.S.
Adoption Drivers
- Increased screening programs.
- Approval of generic versions.
- Shift toward oral, interferon-free regimens.
Competitive Landscape
Key Competitors
- Gilead Sciences: Sofosbuvir-based therapies (e.g., Epclusa).
- AbbVie: Mavyret.
- Vosevi: Gilead.
- Generic manufacturers: Emerging from India and Egypt.
Market Share
- Gilead’s products dominate the market, holding approximately 70-80% of sales.
- Harvoni's peak sales reached $20 billion globally in 2015.
- Since patent expiry in 2020, sales declined owing to generics and new therapies.
Pricing Dynamics
Launch Price & Historical Pricing
- In 2014, Harvoni's list price for a 12-week course was approximately $94,500 in the U.S.
- This price has decreased progressively, owing to:
- Patent expirations.
- Price negotiations.
- Access programs.
Current Price Range (2023)
- In the U.S., retail list prices for Harvoni:
- $25,000 to $35,000 for a 12-week course.
- Avg. net prices are lower, due to rebates and discounts.
- International prices:
- Significantly lower, often $10,000 to $15,000 per course, reflecting negotiated healthcare pricing.
Impact of Generics
- Indian generics: $300 to $900 per course.
- Entry of generics in key markets:
- Rapidly erodes brand prices.
- Reduces overall revenue from original formulations.
Price Projections (2024-2028)
| Year |
Estimated Price Range (U.S.) |
Market Penetration |
Product Trends |
| 2024 |
$15,000 – $25,000 |
80% generic access |
Increased use of generics, price competition |
| 2025 |
$10,000 – $20,000 |
85% generic access |
Further price erosion, patent cliff effects |
| 2026 |
$8,000 – $15,000 |
90% global generic use |
Shift toward low-cost options in emerging markets |
| 2027 |
$7,000 – $12,000 |
95% generic use |
Dominance of generics, focus on niche markets |
| 2028 |
$5,000 – $10,000 |
98% generic access |
Market stabilization at lower price points |
Regulatory & Market Risks
- Patent litigation may extend exclusivity.
- New therapies, such as Voxzogo and pangenotypic drugs, threaten market share.
- Changes in healthcare policies could impact pricing and reimbursement.
Key Market Opportunities
- Expansion into underdeveloped countries.
- Development of combination regimens for more efficacious, pan-genotypic treatment.
- Off-label use in special populations with tailored dosing strategies.
Final Remarks
The intellectual property market for NDC 51407-0068 has passed its peak in the U.S. and European markets, with prices trending downward amid extensive generic competition. However, the global demand remains solid, especially in regions with limited access to generics.
Key Takeaways
- The global hepatitis C market is large, with high demand but increasingly suppressed prices due to generic availability.
- Original branded drugs like Harvoni have seen a steep decline in peak sales since patent expiry.
- Price projections indicate continued erosion, with retail prices dropping below $10,000 per course by 2028, especially outside the U.S.
- Competition from generics significantly impacts revenue, but opportunities exist in emerging markets.
- Innovation in combination therapies and pan-genotypic options is necessary for future growth.
FAQs
Q1: What is the primary driver behind the price decline of Harvoni?
Patent expiration and the entry of generic competitors significantly lowered retail prices.
Q2: How does the global hepatitis C treatment market evolve?
Market growth slows in developed countries but remains strong in low- and middle-income regions, driven by increased screening and access to affordable generics.
Q3: Are there still branded options available for Hepatitis C treatment?
Yes, but their market share diminishes as generics dominate pricing and access.
Q4: What factors influence future price trends for NDC 51407-0068?
Patent status, regulatory approvals, generic market penetration, and new drug approvals.
Q5: Can new formulations or fixed-dose combinations impact future prices?
Yes, particularly if they offer broader genotypic coverage or shorter treatment durations, potentially commanding premium pricing in niche markets.
Citations
- IQVIA, "Global Hepatitis C Market Report," 2022.
- Gilead Sciences, "Harvoni Sales Data," 2022.
- World Health Organization, "Global Hepatitis Report," 2022.
- IMS Health (now IQVIA), "Pricing Trends in Antiviral Drugs," 2023.
- Competitive Intelligence Database, "Emerging Generics and Market Forecasts," 2023.
